Table 1 Patients’ characteristics at inclusion
Groups | [1] | [2] | [3] | [4] | [5] | |
|---|---|---|---|---|---|---|
Characteristics | Enrolled | Exploitable molecular profile | With AGA | With AGA and “matched therapy” | With AGA and “non-matched therapy” | p valuea |
N = 550 (100%) | N = 441 (80%) | N = 393 (71%) | N = 94 (17%) | N = 160 (29%) | ||
Age, years | 1.47E−04 | |||||
Median (range) | 59 (20–84) | 59 (20–84) | 59 (21–83) | 62 (26–83) | 56 (22–81) | |
Sex | 0.749 | |||||
Male | 135 (25%) | 107 (24%) | 92 (23%) | 21 (22%) | 32 (20%) | |
Female | 415 (75%) | 334 (76%) | 301 (77%) | 73 (78%) | 128 (80%) | |
ECOG performance status | 0.720 | |||||
0 | 181 (39%) | 148 (39%) | 127 (37%) | 31 (37%) | 55 (42%) | |
1 | 235 (50%) | 199 (52%) | 179 (52%) | 43 (51%) | 60 (46%) | |
2 | 52 (11%) | 37 (10%) | 35 (10%) | 10 (12%) | 15 (12%) | |
Missing | 82 | 57 | 52 | 10 | 30 | |
Cancer type | 4.74E−02 | |||||
Breast | 268 (49%) | 216 (49%) | 197 (50%) | 42 (45%) | 93 (58%) | |
Lung | 43 (8%) | 34 (8%) | 29 (7%) | 6 (6%) | 12 (8%) | |
Prostate | 39 (7%) | 29 (7%) | 25 (6%) | 10 (11%) | 4 (2%) | |
Ovary | 33 (6%) | 30 (7%) | 23 (6%) | 8 (9%) | 10 (6%) | |
Pancreas | 29 (5%) | 22 (5%) | 22 (6%) | 5 (5%) | 2 (1%) | |
Colorectal | 22 (4%) | 21 (5%) | 19 (5%) | 3 (3%) | 10 (6%) | |
Sarcoma | 18 (3%) | 15 (3%) | 13 (3%) | 3 (3%) | 4 (2%) | |
Endometrial | 17 (3%) | 13 (3%) | 12 (3%) | 5 (5%) | 1 (1%) | |
Uterine cervix | 14 (3%) | 10 (2%) | 10 (3%) | 2 (2%) | 4 (2%) | |
Liver-biliary tractus | 13 (2%) | 10 (2%) | 10 (3%) | 3 (3%) | 5 (3%) | |
Bladder-ureter | 12 (2%) | 10 (2%) | 7 (2%) | 2 (2%) | 2 (1%) | |
Kidney | 9 (2%) | 6 (1%) | 3 (1%) | 0 (0%) | 3 (2%) | |
CUP | 7 (1%) | 5 (1%) | 5 (1%) | 1 (1%) | 3 (2%) | |
Other | 26 (5%) | 20 (5%) | 18 (5%) | 4 (4%) | 7 (4%) | |
Site of the biopsy | 0.078 | |||||
Liver | 213 (41%) | 188 (43%) | 171 (44%) | 34 (37%) | 69 (43%) | |
Lymph node | 86 (17%) | 67 (16%) | 57 (15%) | 18 (19%) | 22 (14%) | |
Lung | 61 (13%) | 50 (11%) | 44 (11%) | 9 (10%) | 22 (14%) | |
Breast | 25 (5%) | 23 (5%) | 19 (5%) | 4 (4%) | 6 (4%) | |
Peritoneum | 23 (4%) | 21 (5%) | 18 (5%) | 2 (2%) | 10 (6%) | |
Skin | 22 (4%) | 19 (4%) | 18 (5%) | 3 (3%) | 10 (6%) | |
Prostate | 10 (2%) | 6 (1%) | 5 (1%) | 3 (3%) | 1 (1%) | |
Pancreas | 6 (1%) | 4 (1%) | 4 (1%) | 2 (2%) | 0 (0%) | |
Pleura | 6 (1%) | 3 (1%) | 3 (1%) | 0 (0%) | 3 (2%) | |
Colorectal | 2 (0%) | 2 (0%) | 2 (1%) | 1 (1%) | 1 (1%) | |
Other | 60 (12%) | 56 (13%) | 50 (13%) | 17 (18%) | 16 (10%) | |
Missing | 36 | 2 | 2 | 1 | 0 | |
Pathological type | 0.788 | |||||
Carcinoma | 522 (94%) | 418 (95%) | 374 (95%) | 91 (97%) | 151 (94%) | |
Sarcoma | 18 (3%) | 15 (3%) | 13 (3%) | 3 (3%) | 4 (2%) | |
Germ cell tumor | 3 (1%) | 3 (1%) | 2 (1%) | 0 (0%) | 2 (1%) | |
Melanoma | 3 (1%) | 3 (1%) | 3 (1%) | 0 (0%) | 2 (1%) | |
Other | 4 (1%) | 2 (0%) | 1 (0%) | 0 (0%) | 1 (1%) | |
Extension stage | 0.506 | |||||
Metastatic | 520 (96%) | 422 (96%) | 376 (96%) | 88 (95%) | 154 (97%) | |
Locally advanced | 24 (4%) | 17 (4%) | 15 (4%) | 5 (5%) | 5 (3%) | |
Missing | 6 | 2 | 2 | 1 | 1 | |
Number of metastatic sites | 0.932 | |||||
Median | 2 | 2 | 2 | 2 | 2 | |
Range | 0 to 7 | 0 to 7 | 0 to 7 | 0 to 7 | 0 to 7 | |
Number of previous lines of chemotherapy for advanced disease | 0.075 | |||||
Median | 3 | 3 | 3 | 3 | 2 | |
Range | 1 to 12 | 1 to 12 | 1 to 12 | 1 to 12 | 1 to 12 | |
Missing | 78 | 57 | 53 | 6 | 29 | |